Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03125226
Other study ID # 9798
Secondary ID NCI-2017-0052597
Status Completed
Phase N/A
First received
Last updated
Start date October 5, 2017
Est. completion date May 18, 2020

Study information

Verified date February 2021
Source University of Washington
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This pilot clinical trial studies how well TracelT hydrogel works in localizing bladder tumors in patients undergoing radiation therapy for bladder cancer. TracelT hydrogel marks the location of a bladder tumor and makes it more visible during imaging tests. Using TracelT hydrogel tissue marker may help doctors learn more about tumor location and altering radiation dosage for bladder cancer.


Description:

PRIMARY OBJECTIVES: I. To utilize the TraceIT hydrogel tissue marker in localizing bladder tumors during transurethral resection of bladder tumors (TURBT). II. To improve identification of gross tumor or tumor bed location in patients receiving chemoradiation treatment for bladder cancers. SECONDARY OBJECTIVES: I. To report adverse events surrounding the placement of the TraceIT tissue marker. II. To calculate the actual dose received by the bladder tumor bed, as delineated by the hydrogel. III. To compare the dosimetric impact to the tumor bed of daily patient alignment to the pelvic bones, versus alignment to the whole bladder, versus alignment to the hydrogel markers. IV. To calculate the amount of normal tissue radiation dose decrease achievable without losing tumor coverage, with better tumor targeting with hydrogel placement. OUTLINE: Patients undergo transurethral resection of bladder tumors and receive TracelT hydrogel via injection. Patients undergo standard of care radiation therapy within 8 weeks of TracelT hydrogel placement.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date May 18, 2020
Est. primary completion date January 1, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically confirmed malignancy of the bladder - No prior cystectomy - Treatment plan for bladder must include at least 4 weeks of daily radiation treatment (most patients will receive chemotherapy concurrent with radiation, but this is not required for trial enrollment) - Patient must undergo TraceIT hydrogel placement within 8 weeks prior to starting radiation therapy for bladder cancer - Participants must have a complete history and physical examination within 60 days of study entry - Participants must be able to provide informed consent for treatment and trial participation - No restrictions on prior treatment to be eligible Exclusion Criteria: - Prior cystectomy - Unable to have TraceIT hydrogel placement < 8 weeks prior to beginning radiation treatment - Treatment for metastatic bladder cancer

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Polyethylene Glycol Hydrogel
Given TracelT hydrogel via injection

Locations

Country Name City State
United States Fred Hutch/University of Washington Cancer Consortium Seattle Washington

Sponsors (2)

Lead Sponsor Collaborator
University of Washington National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in Interfraction Motion of the Marker Measured by Cone Beam Computed Tomography (CT) and x/y/z Coordinates Daily changes will be compared across the patient group as well as within each subjects' treatment course. Baseline up to 8 weeks
Primary Changes in Tumor Bed Size and Shape as Delineated by the Hydrogel and Measured by Cone Beam CT and x/y/z Coordinates Daily changes will be compared across the patient group as well as within each subjects' treatment course. These changes will be tracked during the entire radiation course (typically 4-8 weeks), yielded a distribution of x/y/z positions for each patient. Baseline up to 8 weeks
Secondary Daily Dose of Radiation to the PTV as Based on Alignment to the Hydrogel Location Versus Alignment to Whole Bladder Location Versus Alignment to Bony Antonym Daily pre-radiation imaging will be used to run the radiation treatment plan, to calculate the daily dose to the PTV based on alignment to the hydrogel location, versus alignment to whole bladder location, versus alignment to bony anatomy. Up to 8 weeks
Secondary Daily Dose to the Planning Tumor Volume (PTV) Based on Hydrogel Location Daily pre-radiation imaging will be used to run the radiation treatment plan, to calculate the daily dose to the PTV based on hydrogel location. Total radiation dose to the PTV can then be calculated as the sum of the daily dose. Up to 8 weeks
Secondary Number of Participants With Adverse Events Caused by Hydrogel Graded by the Common Terminology Criteria in Adverse Events version 4.0 Up to 1 year
Secondary Smallest Setup Margin Required for Consistent Coverage of the Gross Tumor Volume (GTV) Daily pre-radiation imaging will be used to identify the smallest setup margin required for consistent coverage of the GTV, which is likely smaller than the current standard of care setup margin of at least 2 cm around the GTV. Up to 8 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05059444 - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Active, not recruiting NCT05399004 - Evaluating Sexual Function in Women Undergoing a Radical Cystectomy for Bladder Cancer
Recruiting NCT03824691 - hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study" Phase 2
Recruiting NCT04502095 - Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy Phase 4
Withdrawn NCT05564416 - Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial Phase 2
Terminated NCT02169284 - Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery Phase 2
Recruiting NCT05519878 - Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers N/A
Active, not recruiting NCT02439060 - PUBMIC (Prophylactic Use of Biologic Mesh in Ileal Conduit) N/A
Recruiting NCT04410302 - Patient-Derived Xenografts to Reduce Cancer Health Disparities
Withdrawn NCT04054752 - Vaccine Response With NT-I7 Phase 1
Terminated NCT03549650 - Prevention and Management of Intravesical BCG-related Lower Urinary Tract Symptoms Phase 2
Completed NCT00469066 - Cone Beam CT Scanning in Lung and Bladder Cancer. N/A
Active, not recruiting NCT03757949 - Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by Surgery Phase 3
Completed NCT03064308 - The Assessment of the Feasibility of a Home Based Exercise Programme in the Older Patient Following Major Surgery N/A
Active, not recruiting NCT02432963 - Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy Phase 1
Active, not recruiting NCT02408406 - PatientCareAnywhere Internet-Based Software in Improving Communication and Education in Patients With Cancer and Their Healthcare Providers N/A
Recruiting NCT06109857 - Bladder Bank (a Prospective Banking Study)
Terminated NCT02145390 - Chemoradiation for Bladder Preservation After Complete Response to Neoadjuvant Chemotherapy N/A
Terminated NCT01245660 - A Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before Cystectomy Phase 0
Withdrawn NCT02438852 - Continuous Infusion of Ropivacaine Hydrochloride in Reducing Pain After Surgery in Patients With Bladder Cancer Phase 3